噻氯匹定对动脉粥样硬化性间歇性跛行患者血小板的抑制作用
Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.
作者信息
Aukland A, Hurlow R A, George A J, Stuart J
出版信息
J Clin Pathol. 1982 Jul;35(7):740-3. doi: 10.1136/jcp.35.7.740.
Abstract
Fifty-one men with atherosclerotic intermittent claudication and haemorheological abnormalities completed a double-blind, one-year randomised trial of Ticlopidine (500 mg/day), a new antiplatelet agent. Ticlopidine caused significant inhibition of platelet aggregation but did not fully correct abnormalities of coagulation, viscosity, and fibrinolysis. There was no significant improvement in walking ability, Doppler ankle-pressure indices, or calf blood flow. Sustained platelet inhibition for 12 months was insufficient to correct the prothrombotic abnormality of extensive atherosclerosis.
摘要
51名患有动脉粥样硬化性间歇性跛行和血液流变学异常的男性完成了一项为期一年的噻氯匹定（500毫克/天）双盲随机试验，噻氯匹定是一种新型抗血小板药物。噻氯匹定可显著抑制血小板聚集，但未完全纠正凝血、粘度和纤维蛋白溶解异常。步行能力、多普勒踝压指数或小腿血流量均无显著改善。持续12个月抑制血小板不足以纠正广泛动脉粥样硬化的血栓前异常。
相似文献
1
Platelet inhibition with Ticlopidine in atherosclerotic intermittent claudication.噻氯匹定对动脉粥样硬化性间歇性跛行患者血小板的抑制作用
J Clin Pathol. 1982 Jul;35(7):740-3. doi: 10.1136/jcp.35.7.740.
2
3
Ticlopidine in the treatment of intermittent claudication: a 21-month double-blind trial.
J Lab Clin Med. 1989 Jul;114(1):84-91.
4
Platelet survival, atherosclerotic intermittent claudication and ticlopidine.血小板存活、动脉粥样硬化性间歇性跛行与噻氯匹定
Atherosclerosis. 1984 Feb;50(2):147-58. doi: 10.1016/0021-9150(84)90018-2.
5
Treatment of intermittent claudication with antiplatelet agents.使用抗血小板药物治疗间歇性跛行。
J Int Med Res. 1990 Sep-Oct;18(5):400-7. doi: 10.1177/030006059001800508.
6
Long-term effects of ticlopidine on lower limb blood flow, ankle/brachial index and symptoms in peripheral arteriosclerosis. A double-blind study. The STIMS Group in Lund. Swedish Ticlopidine Multicenter Study.噻氯匹定对下肢血流、踝/臂指数及外周动脉硬化症状的长期影响。一项双盲研究。隆德的STIMS研究组。瑞典噻氯匹定多中心研究。
Angiology. 1994 Sep;45(9):777-88. doi: 10.1177/000331979404500905.
7
8
Placebo-controlled, double-blind, two-centre trial of ketanserin in intermittent claudication.酮色林治疗间歇性跛行的安慰剂对照、双盲、双中心试验。
Lancet. 1985 Dec 7;2(8467):1268-71. doi: 10.1016/s0140-6736(85)91553-3.
9
Multicenter double-blind study of ticlopidine in the treatment of intermittent claudication and the prevention of its complications.噻氯匹定治疗间歇性跛行及其并发症预防的多中心双盲研究。
Angiology. 1988 Sep;39(9):802-11. doi: 10.1177/000331978803900904.
10
A platelet aggregation inhibitor--ticlopidine--in diabetic nephropathy: a randomized double blind study.
Clin Nephrol. 1984 Mar;21(3):184-7.
引用本文的文献
1
Dual Antiplatelet Therapy: A Concise Review for Clinicians.双联抗血小板治疗：给临床医生的简明综述
Life (Basel). 2023 Jul 18;13(7):1580. doi: 10.3390/life13071580.
2
Prasugrel, a Platelet P2Y12 Receptor Antagonist, Improves Abnormal Gait in a Novel Murine Model of Thrombotic Hindlimb Ischemia.普拉格雷，一种血小板P2Y12受体拮抗剂，可改善血栓性后肢缺血新型小鼠模型中的异常步态。
J Am Heart Assoc. 2016 Apr 6;5(4):e002889. doi: 10.1161/JAHA.115.002889.
3
Antiplatelet agents for intermittent claudication.用于间歇性跛行的抗血小板药物。
Cochrane Database Syst Rev. 2011 Nov 9(11):CD001272. doi: 10.1002/14651858.CD001272.pub2.
4
North of England evidence based guideline development project: guideline on the use of aspirin as secondary prophylaxis for vascular disease in primary care. North of England Aspirin Guideline Development Group.英格兰北部循证指南制定项目：初级保健中阿司匹林用于血管疾病二级预防的指南。英格兰北部阿司匹林指南制定小组。
BMJ. 1998 Apr 25;316(7140):1303-9. doi: 10.1136/bmj.316.7140.1303.
5
Collaborative overview of randomised trials of antiplatelet therapy--I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration.抗血小板治疗随机试验的协作综述——I：各类患者长期抗血小板治疗预防死亡、心肌梗死和中风。抗血小板试验协作组。
BMJ. 1994 Jan 8;308(6921):81-106.
6
Ticlopidine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in platelet-dependent disease states.噻氯匹定。对其药效学、药代动力学特性以及在血小板相关疾病状态下的治疗效果的综述。
Drugs. 1987 Aug;34(2):222-62. doi: 10.2165/00003495-198734020-00003.
7
Ticlopidine. An updated review of its pharmacology and therapeutic use in platelet-dependent disorders.噻氯匹定。其药理学及在血小板相关疾病治疗应用的最新综述。
Drugs. 1990 Aug;40(2):238-59. doi: 10.2165/00003495-199040020-00006.
本文引用的文献
1
Coagulation tests and platelet economy in atherosclerotic and control subjects.动脉粥样硬化患者与对照受试者的凝血试验及血小板状况
Circulation. 1962 Jan;25:114-25. doi: 10.1161/01.cir.25.1.114.
2
Fibrinolytic activity of the blood in intermittent claudication.
Lancet. 1959 Sep 19;2(7099):373-4. doi: 10.1016/s0140-6736(59)91637-x.
3
Studies of coagulation and fibrinolysis of the arterial and venous blood in normal subjects and patients with atherosclerosis.对正常受试者和动脉粥样硬化患者的动脉血和静脉血进行凝血和纤溶研究。
Circulation. 1963 May;27:904-18. doi: 10.1161/01.cir.27.5.904.
4
Haematological stress syndrome in atherosclerosis.动脉粥样硬化中的血液学应激综合征
J Clin Pathol. 1981 May;34(5):464-7. doi: 10.1136/jcp.34.5.464.
5
Effects of long term administration of ticlopidine on platelet function and hemostatic variables.噻氯匹定长期给药对血小板功能和止血变量的影响。
Thromb Res. 1980 Oct 1;20(1):143-8. doi: 10.1016/0049-3848(80)90064-x.
6
Blood rheology.血液流变学
J Clin Pathol. 1980 May;33(5):417-29. doi: 10.1136/jcp.33.5.417.
7
The effect of naftidrofuryl (Praxilene) on intermittent claudication.萘呋胺酯（脉管复康）对间歇性跛行的作用。
Br J Surg. 1980 May;67(5):349-51. doi: 10.1002/bjs.1800670516.
8
A controlled trial of naftidrofuryl (Praxilene) in the treatment of intermittent claudication.萘呋胺酯（脉管复康）治疗间歇性跛行的对照试验。
Br J Surg. 1980 May;67(5):347-8. doi: 10.1002/bjs.1800670515.
9
Hyperviscosity and thrombotic changes in idiopathic and secondary Raynaud's syndrome.特发性和继发性雷诺综合征中的高黏滞血症和血栓形成变化
Br J Haematol. 1980 Aug;45(4):651-8. doi: 10.1111/j.1365-2141.1980.tb07188.x.
10
Haemostatic function and cardiovascular death: early results of a prospective study.止血功能与心血管死亡：一项前瞻性研究的早期结果
Lancet. 1980 May 17;1(8177):1050-4. doi: 10.1016/s0140-6736(80)91498-1.
Zotero 插件